## **REMARKS**

Claims 1-23 and 28-47 have been canceled, without prejudice.

Claims 24-27 are pending.

The applicants elect, with traverse, the subject matter of the Examiner's group I.

The claims read on to the elected subject matter. That is, the applicants submit that the claimed methods relate to the generation of an immune response in an animal or human against the recited polypeptide.

Claims 24 to 27 all have the same goal of raising an immune response against a polypeptide as recited in claim 24. They lead to the same result. According to claims 24 and 25 the polypeptide is provided by direct administration to the animal or human. According to claims 26 and 27 the polypeptide is provided by expression from a polynucleotide. The methods of claims 26 and 27 lead to the production of an immune response against the polypeptide encoded by the polynucleotide, not an immune response against the polynucleotide *per se*. These methods therefore simply provide alternative methods of providing the same recited polypeptide in order to raise an immune response against it.

Examination of at least subject matter of claims 24-27 is therefore requested.

An early and favorable Action on the merits of the claimed invention is requested.

Respectfully submitted,

**NIXON & VANDERHYE P.C.** 

Ву:

Reg. No. 36,663

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000

Facsimile: (703) 816-4100